RESECTED PANCREATIC ADENOCARCINOMA
Clinical trials for RESECTED PANCREATIC ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RESECTED PANCREATIC ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RESECTED PANCREATIC ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New strategy aims to stop pancreatic cancer from coming back
Disease control Recruiting nowThis study is testing a new, personalized approach to chemotherapy for people with pancreatic cancer who have had surgery. After initial chemotherapy and surgery, doctors will look at how much cancer is left and assign patients to one of two different follow-up chemotherapy plans…
Matched conditions: RESECTED PANCREATIC ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New hope to keep pancreatic cancer from returning after surgery
Disease control Recruiting nowThis study is testing whether a new oral drug, daraxonrasib, can help keep pancreatic cancer from coming back after surgery and chemotherapy. It will compare the drug to standard observation (no drug) in 500 patients who have had their tumor surgically removed and completed chemo…
Matched conditions: RESECTED PANCREATIC ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC